Tel Aviv Stock Exchange Ltd. · TASE:TASE
Tel Aviv Stock Exchange — Novolog Group — Investor Presentation (December 2018)
33 slides from Tel Aviv Stock Exchange's investor presentation, December 2018
Slide 1: Novolog Group Presentation
NOVOLOG GROUP PRESENTATION December 2018
Slide 2: Forward-looking information
Forward-looking information • The information included in this presentation is a summary only and does not exhaust all of the information on the Company and its business, nor is it a substitute for inspection of the Periodic Report for 2017, the reports for Q3/2018, the Company’s current reports and
Slide 3: Business Card
Business Card Founded in 1966 Approximately 575 employees The Company was listed on the Strong and stable balance sheet & Tel-Aviv Stock Exchange in 2017 financial position, with no bank debt One of the leading companies in Israel in the logistics of Dividend distribution policy – pharmaceuticals, h
Slide 4: Holding Structure
Holding Structure Public 17.36% Puzis Family via 35.05% Mabat Up Ltd Clal Insurance 6.73% Phoenix Insurance + 6.8% Excellence Investment House 8.6% Harel Insurance and Finance Fimi 10.0% 15.05% Opportunity Yelin Lapidot Fund Investment House Data is updated to December 2018 4 Novolog Group Presentat
Slide 5: Group Structure
Group Structure 100% 70% 100% 100% 70% * 100% 51% *Same legal entity The transaction is expected to be closed on January 1, 2019 5 Novolog Group Presentation | December 2018
Slide 6: Company Timeline
Company Timeline • Acquisition 70% of Dor Pharmaceutical Services • Medicare founded • Acquisition of the balance Acquisition of of Mediplast’s shares CTS’s shares in Novolog Pharm-Up founded Acquisition 80% of Trialog founded • Acquisition 51% of Infomed Mediplast * 1996 1998 1999 2007 2011 2013 20
Slide 7: Trends in Israel
Trends in Israel Uptrend in life expectancy at birth in Israel* Downtrend in hospital beds per 1000 people* (2016, the global average was 72) (OECD average is 3.7) 84 82.6 2.330 81.6 2.224 82 2.089 80 79.0 1.913 1.830 1.796 78 76.6 76 73.9 74 72 71.2 70 68 66 64 1970 1980 1990 2000 2010 2017 1995 20
Slide 8: Trends in Israel
Trends in Israel In Israel, national-public investments in healthcare are steadily Steady rise in the percentage of the chronical patients dropping and are among the lowest in the OECD, while, at the (over 40% of the population) and an increase in the same time, homecare treatments are steadily risi
Slide 9: General Trends in the Global Healthcare Industry
General Trends in the Global Healthcare Industry 9 Novolog Group Presentation | December 2018
Slide 10: Strategy
Strategy Local and multinational companies in the pharmaceutical and medical device Addition and development industries Constant development of various services to make of services to drive homecare products and down healthcare costs services accessible to customers at home Insurers: HMOs, Patients
Slide 11: The Company's vision
The Company’s vision To identify To continue To expand the breakthrough technologies in Israel To construct a establishing and Group’s that help drive down model based on the developing the basket of services healthcare costs and experience Company’s leading to multinational make advanced amassed in
Slide 12: Three operating segments
Three operating segments Home Care & Last Mile* Logistics and related services* Sterilization* Synergies and comprehensive services along the entire health chain *not accounting segments 12 Novolog Group Presentation | December 2018
Slide 13: Logistics and related services
Logistics and related services
Slide 14: Novolog - Distribution
Novolog - Distribution Market leader and strategic partner of 97% of the distribution is carried most of the multinational and local out by the Company’s employees pharmaceutical companies and of medical with a minor use of subcontractors device companies operating in Israel Market leader in pharmac
Slide 15: Novolog – long-term relations as the logistics arm of global pharma
Novolog – long-term relations as the logistics arm of global pharma multinational companies 2015 2014 2013 2012 2008 2007 2006 2004 2001 2000 1998 15 Novolog Group Presentation | December 2018
Slide 16: Trialog clinical trials
Trialog clinical trials Exports Imports Local procurement Randomization Storage Labeling and packaging Distribution Returns Drug destruction Accountability QP services/release The strategic partner of pharmaceutical and CRO companies operating in the clinical trial market in Israel Comprehensive log
Slide 17: Dor Pharmaceutical Services
Dor Pharmaceutical Services Expands the Company’s service offerings to multinational companies Conversion and QP Services Vigilance translation Regulation Clinical research 17 Novolog Group Presentation | December 2018
Slide 18: Home Care and Last Mile
TaN (3) Home Care and Last Mile yar
Slide 19: MediQuip
MediQuip Support echo system for patients Supply of medical devices to healthcare requiring home care institutions and to patients at their homes Home hospitalization Representing global leaders in the fields of: Equipment supply Respiration Instructions Sleep disorders Supply of consumable equipmen
Slide 20: Care for life
Care for life Provides patient-journey and adherence services including digital world via applications and artificial intelligence Increases adherence to drug regimen Maximizes the treatment potential For For patients: HMOs/hospitals: long-term care lower costs Supports patients throughout treatment
Slide 21: MediCare
MediCare Medicare was founded in 2018 as a component of the strategy of providing service to end-customers directly to their homes* - Last Mile Focusing on four main channels: Supplying unique prescription drugs to patients at home and to clients of insurance companies (including selling pharmaceuti
Slide 22: Infomed
Infomed The Group’s digital arm supporting the strategy of providing services to end-customers (Last Mile) Digital advanced-medicine platform offering medical information to the general public and digital solutions for doctors Website with more than one million users per month, providing up-to-date
Slide 23: Sterilization
Sterilization
Slide 24: Mediplast
Mediplast Israel’s main supplier of sterilization services for medical products using ethylene oxide gas Mediplast provides advanced sterilization services to manufacturers of disposable medical equipment, a service constituting the last stage in the manufacturing process before distribution to end-
Slide 25: Growth Engines
| : ‘ TOV J aca. | ES € Peleg as vi eli * a Growth Engines
Slide 26: Continuing to grow and maximize existing capabilities
Continuing to grow and maximize existing capabilities Maximizing Focusing on Growth through Maximizing the Assessments organic Home Care & Last synergetic synergies between the about developing growth Mile as growth acquisitions various operating the operations engines segments overseas 26 Novolog G
Slide 27: Goals for maximizing value during 2019
Goals for maximizing value during 2019 Home dialysis, home rehabilitation Pharmaceutical and home To distribute translations hospice pharmaceuticals printing and directly to homes and conversion sell pharmaceuticals To sell a basket of and additional products to services to insurance multinational c
Slide 28: Financial Information
Financial Information | yn ld y > \ | a co _ od a » a .
Slide 29: Consistent revenue growth (in NIS millions)
Consistent revenue growth (in NIS millions) Reported revenue Managed turnover 4,469 840 3,932 4,045 739 683 690 3,538 2015 2016 2017 01-09/2018 2015 2016 2017 01-09/2018 29 Novolog Group Presentation | December 2018
Slide 30: Growth in adjusted EBITDA (NIS millions)
Growth in adjusted EBITDA* (NIS millions) 51.6 45.9 45.6 43.1 2015 2016 2017 01-09/2018 *After neutralizing expenses and income unrelated to the Company’s ongoing operation; neutralized expenses, such as IPO expenses, revaluation of options to purchase minority interests and other expenses 30 Novolo
Slide 31: Condensed financial data (in NIS millions)
Condensed financial data (in NIS millions) 30.9.2018 31.12.2017 In the pharmaceutical distribution segment – only minor credit exposures Cash 91.6 142.4 • The Company transfers payment only upon receiving Current assets 1,547.6 1,482.0 payment from the customer, or offsets uncollected debts from pay
Slide 32: Summary
Summary Renowned reputation and One of the leading companies long-term relations with in Israel in pharma logistics multinational pharmaceutical and in the healthcare segment companies and HMOs Growth strategy in Home Care Strong and stable statement and end-customer segments, of financial position,
Slide 33: Thank You!
nNeveleq THE HEALTH CARE GROUP Thank You!
Novolog Group — Investor Presentation (December 2018) on 6ix